You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物、金斯瑞、康方及微創機械人跌2.5%-5% 惟3D MEDICINES(01244.HK)屢破頂
港股三連升,恆指在新經濟股、保險股及港交所(00388.HK)帶動高見18,932遇壓,現報18,828,續升168點或0.9%,總成交額634億元。 醫藥相關股今天榮辱互見。日前盈喜料中績毛利增約66%-75%的 3D MEDICINES-B(01244.HK)五連升兼屢創上市新高,今天反覆高見122.9元,現報121.5元,反覆續升2.4%。諾誠健華-B(09969.HK)、歌禮製藥-B(01672.HK)及開拓藥業-B(09939.HK)續升逾1.5%-2%,股價曾分別高見7.5元、2.2元及3.96元。 相反,康方生物-B(09926.HK)表現較差,股價於最近六個交易天除昨日反彈,今早高見37元無以為繼,掉頭向下,午後低見35.1元(接近250天線34.95元),現報35.2元,跌3.6%,較上周二收市價40.15元,累挫12%。 再鼎醫藥-B(09688.HK)、石藥(01093.HK)、國藥(01099.HIK)、康希諾生物(06185.HK)、三葉草生物(02197.HK)、百濟神州(06160.HK)、神威藥業(02877.HK)、金斯瑞(01548.HK)及藥明生物(02269.HK)跌近1.5%-3%,後兩者股價報16.46元及37.5元,反覆跌2.9%及2.5%。 醫療器械股以微創機械人-B(02252.HK)沽壓最大,報20.25元,跌4.9%。貝康醫療-B(02170.HK)六連跌,今天股價跌3%報2.59元,創逾八個月低。先健科技(01302.HK)三連吐,報2.8元(剛為10天線),續跌2.4%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account